Page last updated: 2024-12-07
decane-1,2-diol
Description
decane-1,2-diol : A glycol that is decane bearing two hydroxy substituents located at positions 1 and 2. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 79141 |
| CHEBI ID | 143858 |
| SCHEMBL ID | 51461 |
Synonyms (38)
| Synonym |
|---|
| nsc 28662 |
| einecs 214-288-2 |
| unii-s57m60mi88 |
| s57m60mi88 , |
| ai3-16595 |
| 1119-86-4 |
| nsc28662 |
| nsc-28662 |
| 1,2-decanediol , |
| 1,2-decanediol, 98% |
| D90105 |
| D2720 |
| 1,2-dihydroxydecane |
| CHEBI:143858 |
| decane-1,2-diol |
| FT-0606327 |
| FT-0605120 |
| AKOS015900946 |
| decane 1,2-diol |
| symclariol 344028 |
| symclariol |
| decylene glycol [inci] |
| 1,2-decylene glycol |
| n-decane-1,2-diol |
| decylene glycol [who-dd] |
| SCHEMBL51461 |
| J-640309 |
| J-800477 |
| mfcd00010739 |
| FT-0772143 |
| DTXSID601009388 |
| Q27288644 |
| A853118 |
| AS-56551 |
| SB47801 |
| SB47825 |
| EN300-267732 |
| CS-0198860 |
Roles (3)
| Role | Description |
|---|
| anti-inflammatory agent | Any compound that has anti-inflammatory effects. |
| antioxidant | A substance that opposes oxidation or inhibits reactions brought about by dioxygen or peroxides. |
| human metabolite | Any mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens). |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (2)
| Class | Description |
|---|
| glycol | A diol in which the two hydroxy groups are on different carbon atoms, usually but not necessarily adjacent. |
| volatile organic compound | Any organic compound having an initial boiling point less than or equal to 250 degreeC (482 degreeF) measured at a standard atmospheric pressure of 101.3 kPa. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.80
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 12.80 (24.57) | | Research Supply Index | 1.79 (2.92) | | Research Growth Index | 4.59 (4.65) | | Search Engine Demand Index | 0.00 (26.88) | | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |